ASA: Alteplase Ups Outcomes at 4.5 to 24 Hours After Symptom Onset in Acute...
Significantly more patients with acute ischemic stroke achieved primary outcome of 0 or 1 on modified Rankin scale at 90 days
FDA Approves More Broadly Protective Meningococcal Vaccine
Vaccine helps protect against the A, B, C, W, and Y serogroups of Neisseria meningitidis
FDA Approves Tablet Form of Evrysdi for Spinal Muscular Atrophy
Tablet shows same established efficacy and safety as the Evrysdi oral solution
ASA: Intra-Arterial Tenecteplase Beneficial for Large Vessel Occlusion
Improved likelihood of excellent outcome seen with intra-arterial tenecteplase after successful endovascular recanalization
Offspring of Women With Epilepsy Experience Decreased Bone Metabolism
Exposure to more antiseizure medications also tied to additional issues
Ischemic Stroke Risk Higher With Use of Contemporary Hormonal Contraceptives
Increased risk seen with use of combined pill, progestin-only pills, combined vaginal ring, patch, and progestin-only implant
Many With Overweight, Obesity Discontinue GLP-1 Receptor Agonists Within One Year
Higher discontinuation rates and lower reinitiation rates seen for those without type 2 diabetes
Venous Thromboembolism Risk Higher for Certain Hormonal Contraceptives
Standardized VTE rates highest for combined pills, especially those containing third-generation progestins
RFK Jr. Confirmed as Health Secretary in Near Party-Line Vote
Use of Secondary CVD Prevention Medications Low in Most Countries
Use of one or more classes of medications for secondary CVD prevention peaked at 43.1 percent, decreased to 31.3 percent
